Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

• Status: Recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is a prospective randomized study to examine the effects of exposure to dulaglutide on the prevention of stress-hyperglycemia and the metabolic inflammatory response in the perioperative period

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Emory University
• Collaborator: National Institute of General Medical Sciences (NIGMS)
• Treatments: Anesthetics; Dulaglutide; Immunoglobulin Fc Fragments; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Males or females between the ages of 45 and 80 years and BMI ≥27mg/kg2 undergoing elective CABG surgery

• No previous history of diabetes or hyperglycemia.

Exclusion Criteria:

• Hyperglycemia (BG>125 mg/dl or HbA1c > 6.5%) or previous treatment with antidiabetic agents;

• impaired renal function (GFR < 30 ml/min) or clinically significant hepatic failure;

• subjects with gastrointestinal obstruction expected to require gastrointestinal suction;

• patients with clinically relevant pancreatic or gallbladder disease;

• treatment with oral or injectable corticosteroid;

• mental condition rendering the subject unable to understand the possible consequences of the study;

• pregnancy or breastfeeding at time of enrollment.